
Drs. Maria Pabon and Robert Mentz discuss the role of mineralocorticoid receptor antagonism in heart failure, focusing on nonsteroidal MRAs and risk-based treatment strategies.
CME credits: 0.25 Valid until: 26-03-2027 Claim your CME credit at https://reachmd.com/programs/cme/beyond-steroidal-mras-the-nonsteroidal-mra-lens-in-hf/49198/ In this brief podcast, Drs. Maria Pabon and Robert Mentz explore the evolving role of mineralocorticoid receptor antagonism in heart failure, with emphasis on patients who appear clinically stable yet remain at elevated biologic risk. They contrast steroidal and nonsteroidal MRAs, highlighting differences in receptor selectivity, cardiac-renal distribution, and downstream anti-fibrotic and anti-inflammatory signaling. Faculty address the principle that symptom stability does not equate to disease stability, offering strategies to identify patients with HFpEF or HFmrEF who may benefit from a risk-based treatment approach. =
Guests: Maria Pabon, Robert Mentz
Organizations: ReachMD
Explore listener stats, chart rankings, contacts and more on the ReachMD CME podcast page.